NC-ARETEIA-THERAPEUTICS
Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million. Viking Global Investors and Marshall Wace join the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
The additional capital raised will fund significant expansion of the ongoing Phase III program, to include adding clinical development in Japan along with several additional global markets, expansion of manufacturing activities and additional life-cycle management including development of a once daily formulation.
“We are delighted that leading biotech investors like Viking Global Investors and Marshall Wace have joined the syndicate. Their investment in Areteia further deepens our already strong capitalization position,” said Jorge Bartolome, President and Chief Executive Officer of Areteia. “We are pleased with the strong demand in this investment expansion round as our phase III program in eosinophilic asthma continues to make excellent progress.”
About Areteia Therapeutics
Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies that put respiratory patients in better control of their disease and back in control of their lives. Our initial focus is developing the first potential oral drug for severe eosinophilic asthma.
Areteia’s lead drug candidate is dexpramipexole, and if approved, will be a first-in-class oral eosinophil maturation inhibitor that targets eosinophilic inflammation by lowering blood and tissue eosinophils.
Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. $75 million in expanded financing has now been committed by Viking Global Investors, Marshall Wace and the original syndicate. As a result, the Series A total financing now commits up to $425 million.
Areteia has initiated late-stage development of dexpramipexole in eosinophilic asthma, including three Phase III clinical trials in partnership with Population Health Partners’ development unit, Validae Health.
About Dexpramipexole
Dexpramipexole is an oral small molecule eosinophil lowering drug currently in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation of eosinophils in the bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts to lower eosinophils. Similarly, currently approved injectable anti-IL-5/5R biologic therapies provide clinical benefit through eosinophil lowering. The asthma biologic market is valued today at around $8 billion, with IL-5 biologic therapies approaching $4 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially expand the use of targeted therapy to address Type 2 eosinophilic inflammation in asthma.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213672000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update8.12.2024 18:52:00 CET | Press release
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning andautologous hematopoietic stem cell transplant -- Vertex provides update on progress in bringing CASGEVY to patients - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additio
Andersen Global indvier medlemsvirksomhed i Caribien7.12.2024 01:02:00 CET | Pressemeddelelse
Andersen Global fortsætter med at sætte sit aftryk på det globale landskab, når Robley Baynes, en samarbejdsvirksomhed siden 2020, nu bliver medlemsvirksomhed og tager Andersen-navnet. Andersen in Trinidad and Tobago er den første medlemsvirksomhed i Caribien, der iklæder sig Andersen-brandet i regionen og styrker organisationens globale rækkevidde yderligere. Med partnerne Kendell Robley og Mikhail Baynes som ledere arbejder Andersen in Trinidad and Tobago tæt sammen med kunderne om at levere kvalitetsservice inden for skat, rådgivning, økonomi, selskabsspørgsmål og ledelse. Firmaets kundefokuserede forretningsmodel sikrer integrerede kvalitetsløsninger, der er skræddersyet til at imødekomme de voksende globale krav. "Vores firma har udviklet sig enormt gennem årene, og vores team arbejder flittigt på at levere integrerede kvalitetsløsninger i et forretningslandskab i stadig udvikling," siger Kendell og Mikhail. "Ved at blive medlem af Andersen Global har vi forpligtet os på at drive
Andersen Global styrker sin tilstedeværelse i Malta med endnu en medlemsvirksomhed6.12.2024 23:28:00 CET | Pressemeddelelse
Andersen Global fortsætter med at styrke sin tilstedeværelse i Europa gennem etableringen af Andersen in Malta. Sammen med den eksisterende medlemsadvokatvirksomhed Chetcuti Cauchi Advocates vil der kunne leveres en omfattende pakke af integrerede skattemæssige, juridiske og virksomhedstjenester til private og erhvervskunder i Malta og internationalt. Andersen in Malta leverer en bred vifte af tjenester, herunder skatterådgivning for personer og virksomheder og sikring af deres efterrettelighed vedrørende skatteregler, transfer pricing, dataoverholdelse, global mobilitet og immigration af privatpersoner med stor nettoformue (HNW), ejendomsplanlægning, privat formue-strukturering, rådgivning af familievirksomheder og andre virksomheder. Andersen in Malta har specialiseret sig i at navigere i komplekse regulerings- og skatterammer og rådgiver HNW-personer, familiekontorer og multinationale virksomheder. "I takt med at Malta udvikler sig som en pålidelig destination for privat formue-stru
Lattice Wins 2024 Global Semiconductor Alliance Award6.12.2024 22:00:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $500 Million to $1 Billion in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2024 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their vision, innovation, execution, and future opportunity, as determined by votes from GSA members. “On behalf of the entire team at Lattice, I am honored to accept this prestigious award from the GSA. I am incredibly proud to lead such a talented and dedicated group of individuals who continuously strive to innovate and exceed our customers' expectations. This achievement would not have been possible without the support of our customers and partners. Thank you for being an essential part of our journey,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. “The GSA congratulates
Greenland Resources Welcomes Canada’s Decision to Open a Consulate in Greenland6.12.2024 20:07:00 CET | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) welcomes the Government of Canada’s decision announced today to appoint an Arctic ambassador and open a consulate in Nuuk, Greenland. This follows the new Canadian Arctic Foreign Policy Framework to protect, together with its allies, the economic and military challenges including mineral resources security supply in the Arctic. The Company believes this is relevant for the Project as it is in negotiations to secure Capex funding from Canadian and recently announced European financial institutions and agencies in its press releases dated October 1 and October 15, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241206778181/en/ Greenland Resources Inc. Greenland Resources is a Canadian public company with the Ontario Securities Commission as its principal regulator and is focused on the development of its 100% owned Climax type p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom